These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 414875)

  • 1. [Controlled clinical study of use of dihydroergocristine in cerebral and periferal vascular disorders].
    Calisti G; Biscarini L; Miseo A
    Clin Ter; 1977 Nov; 83(4):371-86. PubMed ID: 414875
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical trials with dihydroergocristine in patients with vascular and cerebral insufficiency].
    Ingelmo M; Vivancos J; Peri J; Balcells Gorina A
    Rev Clin Esp; 1980 Dec; 159(6):399-402. PubMed ID: 6784197
    [No Abstract]   [Full Text] [Related]  

  • 3. [Controlled clinical study on the activity and tolerance of Trivastan].
    Nicrosini F; Pasotti C
    Minerva Med; 1976 May; 67(26):1745-50. PubMed ID: 778674
    [No Abstract]   [Full Text] [Related]  

  • 4. [Controlled double-blind study of the clinical equivalent of two posologic regimens of Hydergine: 1 x 4,5mg compared to 3 x 1,5mg per day].
    Piguet PV; Zoufal Z
    Rev Med Suisse Romande; 1981 Feb; 101(2):157-63. PubMed ID: 7015453
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of Redergam (Latergal) in vascular diseases.
    Kovács E
    Ther Hung; 1986; 34(4):238-42. PubMed ID: 3449979
    [No Abstract]   [Full Text] [Related]  

  • 6. [Letter: Double blind study of hydergine in aged patients].
    Paux G; Boismare F; Delaunay P
    Nouv Presse Med; 1975 Oct; 4(35):2529. PubMed ID: 812060
    [No Abstract]   [Full Text] [Related]  

  • 7. [Controlled clinical trial of dihydroergocristine in neuropsychiatric disorders in cerebrovascular insufficiency].
    Muchnik S
    Boll Chim Farm; 1982 May; 121(5):33S-46S. PubMed ID: 6814466
    [No Abstract]   [Full Text] [Related]  

  • 8. [Experiences with Card-hydergine in patients with cardiac insufficiency and cerebrovascular disorders in professional practice].
    Kohler H
    Med Monatsschr; 1976 Nov; 30(11):516-8. PubMed ID: 792670
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of cerebrovascular insufficiency].
    Cosentino F; Baldassarri R
    Clin Ter; 1979 Mar; 88(6):631-8. PubMed ID: 380878
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapy of chronic cerebrovascular insufficiency. Controlled comparative study of 2 cerebral antihypoxidosis agents].
    Szobor A; Klein M; Bräuer H
    MMW Munch Med Wochenschr; 1982 Oct; 124(41):897-900. PubMed ID: 6815511
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical experiences with the vascular action of dihydroergocristine].
    Tomasi AM; Baggioni GF; Pozzar C
    Minerva Cardioangiol; 1975 Jan; 23(1):7-19. PubMed ID: 806854
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of cerebral wasting diseases with Card-Hydergin].
    Liebhart M
    Med Welt; 1976 Nov; 76(48):2341-6. PubMed ID: 794620
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical evaluation of a new preparation of Ersilan drops in patients with vascular headaches].
    Serclová L
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl; 1988; 31(5):649-55. PubMed ID: 3155391
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of peripheral vascular diseases with dihydroergocristine].
    Moracchini PV; Alfano G; Melandri F
    Minerva Cardioangiol; 1978 Apr; 26(4):277-90. PubMed ID: 97601
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of daily dosages of 6 mg and 20 mg dihydroergocristine in the treatment of chronic cerebro-vascular disease.
    Pagliano FM; Galbiati GC
    J Int Med Res; 1995; 23(4):219-27. PubMed ID: 7589764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic effectiveness and safety of dihydroergocristine. A study of 9,702 patients].
    Mailland F; Zottino G
    Fortschr Med; 1986 Mar; 104(11):239-42. PubMed ID: 3084366
    [No Abstract]   [Full Text] [Related]  

  • 17. DH Ergotoxin (Spofa) sublingual tablets in the treatment of cerebrovascular insufficiency in involution: clinical and experimental psychologic study.
    Misurec J; Morávek Z; Náhunek K; Cesková E; Sláma B; Svestka J
    Act Nerv Super (Praha); 1978 Dec; 20(4):266-7. PubMed ID: 367038
    [No Abstract]   [Full Text] [Related]  

  • 18. Trials of 3,7-dimethyl-1-(5-oxohexyl) xanthine (BL 191) in double-blind tests.
    Buckert D; Harwart D
    Farmaco Prat; 1976 May; 31(5):264-74. PubMed ID: 773679
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of chronic cerebrovascular insufficiency: comparison of nimodipine and dihydroergotoxine].
    Cosmi F; Caresia L; Panebianco G
    Clin Ter; 1986 Feb; 116(3):213-20. PubMed ID: 3698528
    [No Abstract]   [Full Text] [Related]  

  • 20. [The use of Ergocomb in symptoms of cerebrovascular insufficiency].
    Pöthig D; Sauer I; Hansen H; Weidnitzer M
    Z Alternsforsch; 1983; 38(6):443-9. PubMed ID: 6659572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.